Merck KGaA: forms strategic alliance with genOway
(CercleFinance.com) - French biotech company genOway and the German chemicals and pharmaceuticals group Merck have announced reaching a strategic alliance in the field of CRISPR/Cas9 models for the rodent model market, including an exclusive global license and a research partnership.
They will collaborate in the development of new technologies and innovative solutions using CRISPR/Cas9, a so-called "molecular scissors" technique that enables DNA to be cut at a specific place in the genome, in any cell.
genOway will use patented Merck's patented CRISPR/Cas9 technology to generate and sell rodent models worldwide. The financial terms of the agreement were not specified.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
They will collaborate in the development of new technologies and innovative solutions using CRISPR/Cas9, a so-called "molecular scissors" technique that enables DNA to be cut at a specific place in the genome, in any cell.
genOway will use patented Merck's patented CRISPR/Cas9 technology to generate and sell rodent models worldwide. The financial terms of the agreement were not specified.
Copyright (c) 2018 CercleFinance.com. All rights reserved.